
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc has demonstrated strong momentum with its Cabometyx product, particularly in first-line renal cell carcinoma (RCC) and expanding presence in second-line neuroendocrine tumors (NET), supported by a robust growth acceleration. The company's strategic expansion of its gastrointestinal sales team aims to enhance Cabometyx's market share and prepare for the anticipated launch of zanzalintinib in colorectal cancer (CRC), further bolstering its portfolio. Financial projections for Cabometyx sales have been slightly increased for the fiscal years 2026 through 2028, from $2,343 million to $2,352 million in FY26, indicating a strong and sustainable profitability trajectory for the company.
Bears say
Exelixis Inc. has reported a decline in its gross-to-net (GTN) percentage, dropping from 30.2% to 28.5% in the fourth quarter of 2025, primarily due to lower PHS/340B volume, raising concerns about revenue stability. Additionally, Cabometyx sales remained flat sequentially at $545 million, falling short of both internal and consensus estimates, which compounds worries about its growth potential in an increasingly competitive market. The company faces significant risks, including commercial challenges related to Cabometyx, potential unfavorable clinical data from ongoing programs, and the threat of generic competition eroding its existing franchises.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares